CN105816438A - Capsules for treating cardiac neurosis and preparation method thereof - Google Patents
Capsules for treating cardiac neurosis and preparation method thereof Download PDFInfo
- Publication number
- CN105816438A CN105816438A CN201610217477.4A CN201610217477A CN105816438A CN 105816438 A CN105816438 A CN 105816438A CN 201610217477 A CN201610217477 A CN 201610217477A CN 105816438 A CN105816438 A CN 105816438A
- Authority
- CN
- China
- Prior art keywords
- parts
- capsule
- weight
- capsules
- neurosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses capsules for treating cardiac neurosis and a preparation method thereof. The capsules are mainly prepared from the following components in parts by weight: 8 to 16 parts of homeriodictyol, 2 to 5 parts of butylphthalide, 0.8 to 1 part of usnic acid, 0.5 to 0.9 part of Phenobarbital, 5 to 8 parts of catechinic acid, 3 to 6 parts of hyperoside, 6 to 12 parts of N-acetyl glucosamine, 2 to 5 parts of glutathione, 3 to 8 parts of galactomannan, 1 to 3 parts of rutin, 0.8 to 1.6 parts of vitamin B12, 0.3 to 0.9 part of glycyrrhizin, 9 to 15 parts of stachyose, 2 to 5 parts of taurine, 0.5 to 0.8 part of artemisinin, 0.6 to 1.4 parts of cardiac glycosides and 0.08 to 0.16 part of anthocyanin; the capsules also comprise the following auxiliary materials: 38 to 54 parts of a diluent, 2 to 5 parts of a disintegrating agent and 5 to 8 parts of a lubricating agent. According to the capsules disclosed by the invention, a plurality of Western medicines and purely natural components are combined to act; the capsules have the effects of calming mind, soothing nerves, relieving the nerves, and improving dysfunction of cardiovascular systems. The capsules disclosed by the invention are simple in preparation process and convenient to use, and have very good clinical significance.
Description
Technical field
The present invention relates to Drugs for Cardiovascular Diseases technical field, be specifically related to one and treat heart neurosis
Capsule and preparation method thereof.
Background technology
Society, along with the people's continuous pursuit to high living standard, causes self mentally and body
All suffer from the biggest pressure on body, thus the sickness rate of heart neurosis is the most in rising trend, the heart
Visceral never functional disease is uncomfortable also known as functional cardiac, is neurosal a kind of specific type, with cardiovascular system
System malfunction is main performance, can have other performances neurosal concurrently.Clinical symptoms is varied, often
See had palpitation, precordialgia, uncomfortable in chest, breathe hard, dyspnea, dizziness, insomnia, dreaminess etc..The most multiple
Be born in person between twenty and fifty, 20 years old～40 years old person most, be more common in women, especially climacteric women, painstaking effort occur
The symptom of guard system is varied, time light time weight but how the most serious, exist with organic heart disease sometimes simultaneously
Or occur on the basis of the latter, predisposing factors mostly is anxiety, excited, psychic trauma or overworked etc.
Inducement, has palpitation, breathes hard or sensation and movable, tired and the dependency relation of mood, the shape of sleeping such as pareordia is uncomfortable
Condition is likely to can be relevant to primary disease.Its principal pathogenetic mechanism is due to anxiety, anxiety, wound excited, spiritual
The effect of the factors such as wound, the excitement of maincenter and process of inhibition generation obstacle, by the cardiovascular system of vegetative nerve regulating
System, also with getting muddled, causes the symptom that a series of sympathetic tone is too high.Additionally, overworked,
Physical exertion is very few, and blood circulation lacks suitably takes exercise, so that the most movable or a little fatigue does not adapts to,
Thus producing excessive cardiovascular response is also one of cause of disease.
Currently for the treatment of heart neurosis based on psychotherapy, make patient understand the character of primary disease with
Release its misgivings so that it is believe and there is no organic cardiovascular diseases；Avoid the various factor causing aggravation；Drum
Encourage patient oneself to adjust mentality, increase physical training and arrange the daily schedule properly, carry out entertainment, tourism in right amount.But
Give medicine symptomatic treatment can play a multiplier effect simultaneously, from eliminating inducement, correct insomnia, alleviate tight
Open emotion, strengthen immunocompetence, improve cardiovascular function and extremely angularly carry out Drug therapy, therefore can rise
Medicine to many-sided therapeutic effect is the emphasis for this medicine Therapy study.
Summary of the invention
Present invention solves the technical problem that and be to provide a kind of capsule treating heart neurosis and preparation thereof
Method.
The technical scheme is that a kind of capsule treating heart neurosis, described capsule is
By being mainly composed of the following components in parts by weight: Eriodictyol 8-16 part, butylphthalide 2-5 part, Usnea
Acid 0.8-1 part, phenobarbital 0.5-0.9 part, catechin 5-8 part, hyperin 3-6 part, N-acetylamino
Glucose 6-12 part, glutathion 2-5 part, galactomannan 3-8 part, rutin 1-3 part, vitamin
B12 0.8-1.6 part, glycyrrhizin 0.3-0.9 part, stachyose 9-15 part, taurine 2-5 part, arteannuin 0.5-0.8
Part, cardiac glycoside 0.6-1.4 part, anthocyanin 0.08-0.16 part；Described capsule also includes adjuvant: diluent
38-54 part, disintegrating agent 2-5 part, lubricant 5-8 part.
Further, described cardiac glycoside is the compound extracted from Herba Adonidis, containing cardiotonic glycoside in Fu Shou grass roots
Have: cymarin, cymarol, corchoroside A, convallatoxin, K-strophanthus time glycoside-β,
Somalins etc., effectively strengthen myocardial contractility, thus improve Arterial system blood supply situation, have suppression chamber
Conduction and the effect of decreased heart rate, can be used for treating atrial fibrillation, atrial flutter and the supraventricular mistake aroused in interest of paroxysmal
Speed symptom.
Further, described anthocyanin is the pure natural substance extracted from Pericarpium Vitis viniferae, has purged body interior certainly
By base, propagation phylloxanthin, antitumor, anticancer, antiinflammatory, anti-lipid peroxidation and platelet aggregation, prevention
Diabetes, lose weight, protect the effect such as vision.
Further, described diluent is microcrystalline Cellulose, chitosan and cyclodextrin one therein or several
Kind, this type of diluent is the most water insoluble, and has good cohesive, meets state food drug additive mark
Standard, has protein adsorption ability and degradability, can reduce the medicine side effect to human body.
Further, described disintegrating agent be low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, pregelatinized Starch its
In one or several, the granule after this type of disintegrate is the most tiny, beneficially the dissolution of medicine, disintegrating property
Superior.
Further, described lubricant is magnesium stearate, micropowder silica gel and Pulvis Talci one therein or several
Kind, this series lubricant agent has good mobility and compressibility, stable chemical nature, improves the stream of drug particles
Dynamic property.
The preparation method of a kind of capsule treating heart neurosis is:
(1) distilled water that the diluent of described composition by weight adds 5-8 times amount is ground to pasty state, makes pasty state
Liquid, standby；
(2) by the Eriodictyol of described composition by weight, butylphthalide, usnic acid, phenobarbital, catechu
Element, hyperin, 2-Acetamido-2-deoxy-D-glucose, glutathion, galactomannan, rutin, vitamin
After B12, glycyrrhizin, stachyose, taurine, arteannuin, agglutinin, anthocyanin are ground respectively, machinery is mixed
Close, cross 300 mesh sieves, make hybrid medicine fine powder, be then added in pasty liquid prepared by (1), pour glue into
In body mill, colloid mill has good rotproofness and wearability, makes the pollution-free health of processed material pure,
Homogenizing emulsion that can well be stable and suspension, only need single treatment just can obtain the granular size concentrated
Distribution, excellent uniformity, open machine, grind 30 minutes, prepare medicinal mixture；
(3) by coating materials sterile solid corn starch 10-15 part and mass concentration be 65-80% ethanol solution by
After the weight ratio stirring of 1:3-5, after standing 8-12h, addition plasticizer phthalic acid dibutyl ester 5-8 part,
Opacifier vanillin 2-5 part, is configured to coating solution, standby；
(4) weigh the disintegrating agent of described composition by weight, hybrid medicine prepared by lubricant and (2) uses wet method
After shear-mixed is uniform in mixer, dry granulating machine is used to pelletize, the granule of screening 20-40 mesh, its excess
Material returns granulator to be continued to pelletize, and is repeated several times by pharmaceutical granulation fully；
(5) by (4) prepare granule put in top-jet-type fluidized-bed coating machine, use nebulisation operation system and
Coating mode makes granulation, enrobing processes and drying process once complete in fluid bed, reduces energy consumption, by (3)
The coating solution of preparation is sprayed onto on granule by atomizing lance, and coating weight gain is 1-2%, is subsequently filled capsule, bag
Transport and store and deposit, i.e. prepare the capsule of described treatment heart neurosis.
The invention has the beneficial effects as follows: by multiple Western medicine combination of active principles, Eriodictyol, taurine, youngster
Theine, galactomannan, rutin, cardiac glycoside, anthocyanin synergy have protecting myocardial cell, support
The effect of the preventing and treating cardiovascular system diseases such as arrhythmia；Vitamin B12, butylphthalide, phenobarbital,
Hyperin synergy can improve nervous function damage and promote neurological recovery, sedation-analgesia,
Suppression neural excitation, intense strain of releiving, hypnotic；Glycyrrhizin, stachyose, glutathion, Usnea
Acid, arteannuin, 2-Acetamido-2-deoxy-D-glucose synergy strengthen human immune system, and antioxidation, in purged body
Free radical.Capsule of the present invention can effectively improve the dysfunction of cardiovascular system, fundamentally treats heart
The clinical symptoms such as neurosis cardiopalmus then, sensation of oppression over the chest with shortness of breath, agitation, insomnia and dreamful sleep, preparation technology is simple,
Easy to use, it is adaptable to the popularization of clinical treatment.
Detailed description of the invention
Embodiment 1:
A kind of capsule treating heart neurosis, described capsule by main by following weight portion
One-tenth is grouped into: Eriodictyol 8 parts, butylphthalide 2 parts, usnic acid 0.8 part, phenobarbital 0.5 part,
Catechin 5 parts, hyperin 3 parts, 2-Acetamido-2-deoxy-D-glucose 6 parts, glutathion 2 parts, galactomannan
Polysaccharide 3 parts, rutin 1 part, vitamin B12 0.8 part, glycyrrhizin 0.3 part, 9 parts of stachyose, cattle
Sulfonic acid 2 parts, arteannuin 0.5 part, cardiac glycoside 0.6 part, anthocyanin 0.08 part；Described capsule also includes
Adjuvant: diluent 38 parts, disintegrating agent 2 parts, lubricant 5 parts.
Wherein, described cardiac glycoside is the compound extracted from Herba Adonidis, has containing cardiotonic glycoside in Fu Shou grass roots:
Cymarin, cymarol, corchoroside A, convallatoxin, K-strophanthus time glycoside-β, rope
Malins etc., effectively strengthen myocardial contractility, thus improve Arterial system blood supply situation, have suppression chamber and pass
Lead the effect with decreased heart rate, can be used for treating atrial fibrillation, atrial flutter and paroxysmal supraventricular tachycardia
Symptom.Described anthocyanin is the pure natural substance extracted from Pericarpium Vitis viniferae, has removing interior free yl, increasing
Grow phylloxanthin, antitumor, anticancer, antiinflammatory, anti-lipid peroxidation and platelet aggregation, prevention diabetes,
The effects such as fat-reducing, protection vision.Described diluent is microcrystalline Cellulose, and this type of diluent is the most water insoluble,
And there is good cohesive, meet state food drug additive standard, have protein adsorption ability and degradability,
The medicine side effect to human body can be reduced.Described disintegrating agent is low-substituted hydroxypropyl cellulose, after this type of disintegrate
Granule the most tiny, the beneficially dissolution of medicine, disintegrating property is superior.Described lubricant is magnesium stearate,
This series lubricant agent has good mobility and compressibility, stable chemical nature, improves the mobility of drug particles.
The preparation method of a kind of capsule treating heart neurosis is:
(1) distilled water that the diluent of described composition by weight adds 5 times amount is ground to pasty state, makes pasty liquid,
Standby；
(2) by the Eriodictyol of described composition by weight, butylphthalide, usnic acid, phenobarbital, catechu
Element, hyperin, 2-Acetamido-2-deoxy-D-glucose, glutathion, galactomannan, rutin, vitamin
After B12, glycyrrhizin, stachyose, taurine, arteannuin, agglutinin, anthocyanin are ground respectively, machinery is mixed
Close, cross 300 mesh sieves, make hybrid medicine fine powder, be then added in pasty liquid prepared by (1), pour glue into
In body mill, colloid mill has good rotproofness and wearability, makes the pollution-free health of processed material pure,
Homogenizing emulsion that can well be stable and suspension, only need single treatment just can obtain the granular size concentrated
Distribution, excellent uniformity, open machine, grind 30 minutes, prepare medicinal mixture；
(3) it is that 65% ethanol solution is according to 1:3 by coating materials sterile solid corn starch 10 parts and mass concentration
Weight ratio stirring after, stand after 8h, add plasticizer phthalic acid dibutyl ester 5 parts, opacifier chinese cymbidium
Element 2 parts, is configured to coating solution, standby；
(4) weigh the disintegrating agent of described composition by weight, hybrid medicine prepared by lubricant and (2) uses wet method
After shear-mixed is uniform in mixer, uses dry granulating machine to pelletize, screen the granule of 20 mesh, rest materials
Return granulator to continue to pelletize, be repeated several times by pharmaceutical granulation fully；
(5) by (4) prepare granule put in top-jet-type fluidized-bed coating machine, use nebulisation operation system and
Coating mode makes granulation, enrobing processes and drying process once complete in fluid bed, reduces energy consumption, by (3)
The coating solution of preparation is sprayed onto on granule by atomizing lance, and coating weight gain is 1%, is subsequently filled capsule, packaging
Storage, i.e. prepares the capsule of described treatment heart neurosis.
Embodiment 2:
A kind of capsule treating heart neurosis, described capsule by main by following weight portion
One-tenth is grouped into: Eriodictyol 12 parts, butylphthalide 3.5 parts, usnic acid 0.9 part, phenobarbital 0.7 part,
Catechin 6.5 parts, hyperin 4.5 parts, 2-Acetamido-2-deoxy-D-glucose 9 parts, glutathion 3.5 parts, half
Breast mannan 5.5 parts, rutin 2 parts, vitamin B12 1.2 parts, glycyrrhizin 0.6 part, stachyose
12 parts, taurine 3.5 parts, arteannuin 0.65 part, cardiac glycoside 1 part, anthocyanin 0.12 part；Described glue
Wafer also includes adjuvant: diluent 46 parts, disintegrating agent 3.5 parts, lubricant 6.5 parts.
Wherein, described cardiac glycoside is the compound extracted from Herba Adonidis, has containing cardiotonic glycoside in Fu Shou grass roots:
Cymarin, cymarol, corchoroside A, convallatoxin, K-strophanthus time glycoside-β, rope
Malins etc., effectively strengthen myocardial contractility, thus improve Arterial system blood supply situation, have suppression chamber and pass
Lead the effect with decreased heart rate, can be used for treating atrial fibrillation, atrial flutter and paroxysmal supraventricular tachycardia
Symptom.Described anthocyanin is the pure natural substance extracted from Pericarpium Vitis viniferae, has removing interior free yl, increasing
Grow phylloxanthin, antitumor, anticancer, antiinflammatory, anti-lipid peroxidation and platelet aggregation, prevention diabetes,
The effects such as fat-reducing, protection vision.Described diluent is chitosan, and this type of diluent is the most water insoluble, and tool
There is good cohesive, meet state food drug additive standard, have protein adsorption ability and degradability, can
To reduce the medicine side effect to human body.Described disintegrating agent is polyvinylpolypyrrolidone, and the granule after this type of disintegrate is non-
The most tiny, the beneficially dissolution of medicine, disintegrating property is superior.Described lubricant is micropowder silica gel, this type of profit
Lubrication prescription has good mobility and compressibility, stable chemical nature, improves the mobility of drug particles.
The preparation method of a kind of capsule treating heart neurosis is:
(1) distilled water that the diluent of described composition by weight adds 6.5 times amount is ground to pasty state, makes pasty state
Liquid, standby；
(2) by the Eriodictyol of described composition by weight, butylphthalide, usnic acid, phenobarbital, catechu
Element, hyperin, 2-Acetamido-2-deoxy-D-glucose, glutathion, galactomannan, rutin, vitamin
After B12, glycyrrhizin, stachyose, taurine, arteannuin, agglutinin, anthocyanin are ground respectively, machinery is mixed
Close, cross 300 mesh sieves, make hybrid medicine fine powder, be then added in pasty liquid prepared by (1), pour glue into
In body mill, colloid mill has good rotproofness and wearability, makes the pollution-free health of processed material pure,
Homogenizing emulsion that can well be stable and suspension, only need single treatment just can obtain the granular size concentrated
Distribution, excellent uniformity, open machine, grind 30 minutes, prepare medicinal mixture；
(3) by coating materials sterile solid corn starch 12.5 parts and mass concentration be 72.5% ethanol solution according to
After the weight ratio stirring of 1:4, after standing 10h, add plasticizer phthalic acid dibutyl ester 6.5 parts, shading
Agent vanillin 3.5 parts, is configured to coating solution, standby；
(4) weigh the disintegrating agent of described composition by weight, hybrid medicine prepared by lubricant and (2) uses wet method
After shear-mixed is uniform in mixer, uses dry granulating machine to pelletize, screen the granule of 30 mesh, rest materials
Return granulator to continue to pelletize, be repeated several times by pharmaceutical granulation fully；
(5) by (4) prepare granule put in top-jet-type fluidized-bed coating machine, use nebulisation operation system and
Coating mode makes granulation, enrobing processes and drying process once complete in fluid bed, reduces energy consumption, by (3)
The coating solution of preparation is sprayed onto on granule by atomizing lance, and coating weight gain is 1.5%, is subsequently filled capsule, bag
Transport and store and deposit, i.e. prepare the capsule of described treatment heart neurosis.
Embodiment 3:
A kind of capsule treating heart neurosis, described capsule by main by following weight portion
One-tenth is grouped into: Eriodictyol 16 parts, butylphthalide 5 parts, usnic acid 1 part, phenobarbital 0.9 part,
Catechin 8 parts, hyperin 6 parts, 2-Acetamido-2-deoxy-D-glucose 12 parts, glutathion 5 parts, gala are sweet
Dew polysaccharide 8 parts, rutin 3 parts, vitamin B12 1.6 parts, glycyrrhizin 0.9 part, 15 parts of stachyose,
Taurine 5 parts, arteannuin 0.8 part, cardiac glycoside 1.4 parts, anthocyanin 0.16 part；Described capsule also wraps
Include adjuvant: diluent 54 parts, disintegrating agent 5 parts, lubricant 8 parts.
Wherein, described cardiac glycoside is the compound extracted from Herba Adonidis, has containing cardiotonic glycoside in Fu Shou grass roots:
Cymarin, cymarol, corchoroside A, convallatoxin, K-strophanthus time glycoside-β, rope
Malins etc., effectively strengthen myocardial contractility, thus improve Arterial system blood supply situation, have suppression chamber and pass
Lead the effect with decreased heart rate, can be used for treating atrial fibrillation, atrial flutter and paroxysmal supraventricular tachycardia
Symptom.Described anthocyanin is the pure natural substance extracted from Pericarpium Vitis viniferae, has removing interior free yl, increasing
Grow phylloxanthin, antitumor, anticancer, antiinflammatory, anti-lipid peroxidation and platelet aggregation, prevention diabetes,
The effects such as fat-reducing, protection vision.Described diluent is microcrystalline Cellulose, chitosan and cyclodextrin therein
Planting or several, this type of diluent is the most water insoluble, and has good cohesive, meets state food medicine
Additive standard, has protein adsorption ability and degradability, can reduce the medicine side effect to human body.Described
Disintegrating agent be low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, pregelatinized Starch therein one or several, this
Granule after class disintegrate is the most tiny, beneficially the dissolution of medicine, and disintegrating property is superior.Described lubricant is
Magnesium stearate, micropowder silica gel and Pulvis Talci therein one or several, this series lubricant agent has well flowing
Property and compressibility, stable chemical nature, improve the mobility of drug particles.
The preparation method of a kind of capsule treating heart neurosis is:
(1) distilled water that the diluent of described composition by weight adds 5-8 times amount is ground to pasty state, makes pasty state
Liquid, standby；
(2) by the Eriodictyol of described composition by weight, butylphthalide, usnic acid, phenobarbital, catechu
Element, hyperin, 2-Acetamido-2-deoxy-D-glucose, glutathion, galactomannan, rutin, vitamin
After B12, glycyrrhizin, stachyose, taurine, arteannuin, agglutinin, anthocyanin are ground respectively, machinery is mixed
Close, cross 300 mesh sieves, make hybrid medicine fine powder, be then added in pasty liquid prepared by (1), pour glue into
In body mill, colloid mill has good rotproofness and wearability, makes the pollution-free health of processed material pure,
Homogenizing emulsion that can well be stable and suspension, only need single treatment just can obtain the granular size concentrated
Distribution, excellent uniformity, open machine, grind 30 minutes, prepare medicinal mixture；
(3) by coating materials sterile solid corn starch 10-15 part and mass concentration be 65-80% ethanol solution by
After the weight ratio stirring of 1:3-5, after standing 8-12h, addition plasticizer phthalic acid dibutyl ester 5-8 part,
Opacifier vanillin 2-5 part, is configured to coating solution, standby；
(4) weigh the disintegrating agent of described composition by weight, hybrid medicine prepared by lubricant and (2) uses wet method
After shear-mixed is uniform in mixer, dry granulating machine is used to pelletize, the granule of screening 20-40 mesh, its excess
Material returns granulator to be continued to pelletize, and is repeated several times by pharmaceutical granulation fully；
(5) by (4) prepare granule put in top-jet-type fluidized-bed coating machine, use nebulisation operation system and
Coating mode makes granulation, enrobing processes and drying process once complete in fluid bed, reduces energy consumption, by (3)
The coating solution of preparation is sprayed onto on granule by atomizing lance, and coating weight gain is 1-2%, is subsequently filled capsule, bag
Transport and store and deposit, i.e. prepare the capsule of described treatment heart neurosis.
The capsule of the present invention application in treatment heart neurosis:
One, animal toxicity test:
Test method: healthy male SD rat 50, body weight 200～230g, is randomly divided into two groups, warp
Determine after quarantine that each group of rat vital sign is normal and without individual variation, has comparability.By the embodiment of the present invention
The capsule of 2 preparations is made into two dosage groups of 1g/kg, 2g/kg, is hybridly prepared into 10ml/1g with pure water respectively,
Rat is carried out gavage, is administered once every 6h, continuous medicine feed 7 days, observe the sign situation of change of rat.
Result of the test: rat does not shows any abnormalities reaction, also without dead, carries out anatomy experiment to rat, has no
Major organs has any damage, illustrates that capsule of the present invention has no overt toxicity, drug safety.
Two, clinical trial:
1. clinical case selects and is grouped: inventor collects the patients of cardiac neurosis dysfunction that 80 examples are made a definite diagnosis altogether,
It is randomly divided into four groups, often organizes 20 people, three groups of test group, one group of matched group, four groups of sexes, age, state of an illness
Etc. data there are no significant difference, there is comparability.
2. diagnostic criteria: clinical manifestation is chest pain, cardiopalmus, cough, dyspnea, loss of appetite etc., sign
Show themselves in that the cardiovascular function such as tachycardia, arrhythmia is abnormal.
3. test method: respectively give test group patient take embodiment 1, embodiment 2, embodiment 3 preparation
Capsule, takes 2 times, each 0.5g every day, within 10 days, is a course for the treatment of, and experimental period is three courses for the treatment of,
Matched group patient carries out psychotherapy and does not do any Drug therapy.
4. criterion of therapeutical effect and therapeutic outcome
1 three groups of comparitive study of table
| The medicine taken | Case number | Average cure time (my god) | Untoward reaction |
| Embodiment 1 | 20 | 11 | 0 |
| Embodiment 2 | 20 | 8 | 0 |
| Embodiment 3 | 20 | 10 | 0 |
| Matched group | 20 | 22 | 0 |
5. conclusion: during clinical trial, the patient accepting capsule of the present invention treatment finds no any bad
Reaction, as seen from the data in Table 1, capsule of the present invention has good curative effect to treatment heart neurosis,
Shorten common treatment cycle, be the safe and effective medicine for the treatment of heart neurosis, have and well face
Bed meaning.
Although the present invention being described and illustrated with reference to its specific embodiments, but those skilled in the art will appreciate that
Arrive, without departing from the spirit and scope of the present invention it can be variously modified, revise and replace.
Such as, due to the change of responding ability of the people of treated particular condition, beyond preferred dose as explained above
Effective dose may be suitable for.Similarly, it was observed that pharmacology respond may basis and rely on selected given activity
Compound or whether there is pharmaceutical carrier and preparation type and mode of administration used and become, according to the mesh of the present invention
And practice be contemplated in result this kind of expection change or difference.Therefore, the invention is intended to only by following patent
The scope required limits and these claim should be explained in rational degree as broadly as possible.
Claims (7)
1. the capsule treating heart neurosis, it is characterised in that described capsule is by leading
It is composed of the following components in parts by weight: Eriodictyol 8-16 part, butylphthalide 2-5 part, usnic acid 0.8-1
Part, phenobarbital 0.5-0.9 part, catechin 5-8 part, hyperin 3-6 part, 2-Acetamido-2-deoxy-D-glucose
6-12 part, glutathion 2-5 part, galactomannan 3-8 part, rutin 1-3 part, vitamin B12 0.8-1.6
Part, glycyrrhizin 0.3-0.9 part, stachyose 9-15 part, taurine 2-5 part, arteannuin 0.5-0.8 part, strong
Heart glycosides 0.6-1.4 part, anthocyanin 0.08-0.16 part；Described capsule also includes adjuvant: diluent 38-54
Part, disintegrating agent 2-5 part, lubricant 5-8 part.
A kind of capsule treating heart neurosis, it is characterised in that
Described cardiac glycoside is the compound extracted from Herba Adonidis.
A kind of capsule treating heart neurosis, it is characterised in that
Described anthocyanin is extracted from Pericarpium Vitis viniferae.
A kind of capsule treating heart neurosis, it is characterised in that
Described diluent be microcrystalline Cellulose, chitosan and cyclodextrin therein one or several.
A kind of capsule treating heart neurosis, it is characterised in that
Described disintegrating agent is low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, pregelatinized Starch one therein or several
Kind.
A kind of capsule treating heart neurosis, it is characterised in that
Described lubricant be magnesium stearate, micropowder silica gel and Pulvis Talci therein one or several.
7. a kind of capsule treating heart neurosis as described in claim 1-6, it is characterised in that
Preparation method is:
(1) distilled water that the diluent of described composition by weight adds 5-8 times amount is ground to pasty state, makes pasty state
Liquid, standby；
(2) by the Eriodictyol of described composition by weight, butylphthalide, usnic acid, phenobarbital, catechu
Element, hyperin, 2-Acetamido-2-deoxy-D-glucose, glutathion, galactomannan, rutin, vitamin
After B12, glycyrrhizin, stachyose, taurine, arteannuin, cardiac glycoside, anthocyanin are ground respectively, machinery is mixed
Close, cross 300 mesh sieves, make hybrid medicine fine powder, be then added in pasty liquid prepared by (1), pour glue into
In body mill, open machine, grind 30 minutes, prepare medicinal mixture；
(3) it is after 65-80% ethanol solution stirs according to the weight ratio of 1:3-5 by coating materials and mass concentration,
After standing 8-12h, add plasticizer, opacifier, be configured to coating solution, standby；
(4) weigh the disintegrating agent of described composition by weight, hybrid medicine prepared by lubricant and (2) uses wet method
After shear-mixed is uniform in mixer, dry granulating machine is used to pelletize, the granule of screening 20-40 mesh, its excess
Material returns granulator to be continued to pelletize；
(5) granule that (4) prepare is put in fluidized-bed coating machine, the coating solution that (3) prepare is passed through
Atomizing lance is sprayed onto on granule, and coating weight gain is 1-2%, is subsequently filled capsule, package storage, i.e. prepares institute
The capsule of the treatment heart neurosis stated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610217477.4A CN105816438A (en) | 2016-04-08 | 2016-04-08 | Capsules for treating cardiac neurosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610217477.4A CN105816438A (en) | 2016-04-08 | 2016-04-08 | Capsules for treating cardiac neurosis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105816438A true CN105816438A (en) | 2016-08-03 |
Family
ID=56526654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610217477.4A Pending CN105816438A (en) | 2016-04-08 | 2016-04-08 | Capsules for treating cardiac neurosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105816438A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101664401A (en) * | 2009-08-25 | 2010-03-10 | 华东师范大学 | Application of usnic acid in preparation of drugs inhibiting angiogenesis |
| CN104366505A (en) * | 2014-12-10 | 2015-02-25 | 韦星平 | Antioxidant natural food additive |
| TW201538155A (en) * | 2014-03-10 | 2015-10-16 | Benjamin M Yu | AI-helper composition and method for delivering an AI compound to a subject |
| CN105348245A (en) * | 2015-12-01 | 2016-02-24 | 陕西嘉禾生物科技股份有限公司 | Eriodictyol synthesis method |
-
2016
- 2016-04-08 CN CN201610217477.4A patent/CN105816438A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101664401A (en) * | 2009-08-25 | 2010-03-10 | 华东师范大学 | Application of usnic acid in preparation of drugs inhibiting angiogenesis |
| TW201538155A (en) * | 2014-03-10 | 2015-10-16 | Benjamin M Yu | AI-helper composition and method for delivering an AI compound to a subject |
| CN104366505A (en) * | 2014-12-10 | 2015-02-25 | 韦星平 | Antioxidant natural food additive |
| CN105348245A (en) * | 2015-12-01 | 2016-02-24 | 陕西嘉禾生物科技股份有限公司 | Eriodictyol synthesis method |
Non-Patent Citations (1)
| Title |
|---|
| 李天杰等: "丁基苯酞对血管性痴呆患者自由基及血液流变学的影响", 《中国现代药物应用》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2559784C2 (en) | Composition for mitigating fatigue, formulation and using them | |
| CN104606513B (en) | A kind of Chinese medicine for treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN105919136A (en) | Nutrition supplement composition with fatigue resisting and immunity improving effects and preparation and preparation method thereof | |
| CN113413461A (en) | Medicine for resisting senile dementia and its preparing method | |
| CN111743934A (en) | Traditional Chinese medicine composition for regulating intestinal flora and application thereof | |
| CN114916604A (en) | Gel candy with health care function | |
| CN101612159A (en) | The application of chemical compound 20 (S)-ginsenoside Rh2 in the preparation anti-fatigue medicament | |
| CN104138376A (en) | A sustained release agent improving anoxia endurance | |
| CN106074464A (en) | Cannabidiol application in preparation treatment gout medicine | |
| CN104922383B (en) | One improves myocardial ischemia and ARR compositions | |
| CN105816438A (en) | Capsules for treating cardiac neurosis and preparation method thereof | |
| WO2015018471A1 (en) | Pni (psychoneuroimmunium) lobbyist cell protection | |
| CN110269897B (en) | Composition for resisting fatigue and improving sleep and application thereof | |
| CN103479895A (en) | Heart comforting and brain clearing traditional Chinese medicine composition | |
| CN100531791C (en) | Antineoplastic, anti-cancer drugs | |
| CN103800341B (en) | The combination medicine of anti-curing oncoma | |
| CN105663193B (en) | Rice washing water prepared pseudo-ginseng powder as well as preparation and preparation method thereof | |
| CN101112405B (en) | Drug for curing coronary disease and method for preparing the same | |
| US11684631B2 (en) | Method of treating cancer with composition of traditional Chinese medicine and its preparation method thereof | |
| CN1248684C (en) | Chinese medicine powder for curing cardiovascular disease and preparing method thereof | |
| CN101991645A (en) | Preparation for treating coronary heart disease and preparation method thereof | |
| CN101991829A (en) | Medicament for treating stomach illness | |
| CN107998289A (en) | It is a kind of that there is alleviation visual fatigue, the traditional Chinese medicine preparation product of strengthen immunity characteristic | |
| CN101176770B (en) | Pharmaceutical composition of folium ginkgo and cattail pollen | |
| CN105709228A (en) | Medicine composition used for treating myocardial ischemia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160803 |